China’s coronavirus vaccine gets special military drug approval
|The risk sentiment is getting some lift from the encouraging Chinese vaccine news that came in over the weekend, with the influential media outlet, Global Times, offering some additional insights on the vaccine story.
Key takeaways
“Chinese biopharmaceutical firm CanSino Biologics Inc developed the vaccine in conjunction with a military research team.”
“Jointly developed by CanSino and the Institute of Biotechnology under the Academy of Military Medical Sciences.”
“Phase 1 and phase 2 clinical trials for Ad5-nCoV have been conducted.”
“The overall clinical results indicate Ad5-nCoV has the potential to prevent diseases caused by SARS-CoV-2.”
“CanSino announced its collaboration with the Canadian National Research Council on clinical trials for the recombinant vaccine in May.”
Over the weekend, Sinopharm Group announced that in partnership with the Chinese Centre for Disease Control and Prevention, they are advancing on clinical trials to develop a COVID-19 vaccine.
Sinopharm Group noted that its second vaccine has been found to be safe and able to generate high concertation of antibodies among participants in phase I and II clinical trials.
Market reaction
Now, with the Chinese military approval for the drug, the market mood in Asia has somewhat improved, with the risk assets such as the Aussie dollar, US equity futures etc, attempting a minor bounce.
AUD/USD has bounced-off lows at 0.6847 to now trade around 0.6875 while S&P 500 futures gain 0.22% to regain the 3K mark. USD/JPY holds steady around 107.25.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.